Physician profile
Gary D Thomas
NPI 1407895261
$3,591.90
in general payments reported to CMS, 2019-2025
31 companies · $412 in 2025
The $412 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $885 · 2020: $693 · 2021: $293 · 2022: $116 · 2023: $655 · 2024: $538 · 2025: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,605.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,604.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $550.62 | 2019-2025 | Repatha, Repatha, Otezla |
| Novo Nordisk INC | $462.94 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $391.38 | 2019-2020 | |
| Emd Serono, INC. | $331.37 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $305.61 | 2019-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $261.59 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $152.93 | 2020-2025 | Xifaxan |
| Pfizer INC. | $150.66 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $149.56 | 2023-2025 | Rexulti |
| Mylan Specialty L.P. | $136.16 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.17 | 2019-2021 | |
| Atland Pharmaceuticals, LLC | $75.92 | 2024 | Tolmetin Sodium, Orphenadrine Citrate, Aspirin and Caffeine |
| Dexcom, INC. | $67.08 | 2022-2024 | Dexcom G6 Transmitter |
| Neurocrine Biosciences, INC. | $64.41 | 2023-2025 | Ingrezza |
| Lundbeck LLC | $62.16 | 2023-2025 | Rexulti |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $56.89 | 2020-2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $41.73 | 2019 | |
| Sanofi Pasteur INC. | $34.16 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $32.13 | 2023 | Austedo Xr |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.98 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.27 | 2025 | Caplyta |
| Exact Sciences Corporation | $18.66 | 2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $16.50 | 2024 | |
| Abbott Laboratories | $15.73 | 2021 | |
| Merck Sharp & Dohme LLC | $13.97 | 2019 | |
| Avanir Pharmaceuticals, INC. | $12.64 | 2020 | |
| Genentech USA, INC. | $12.62 | 2019 | |
| Phathom Pharmaceuticals, INC. | $12.11 | 2024 | Voquezna |
| Allergan, INC. | $12.08 | 2019 | |
| Esperion Therapeutics, INC. | $11.52 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.